Kuate, Seraphin and Stahl-Hennig, Chnistiane and Stoiber, Heribert and Nehinda, Godwin and Floto, Anja and Franz, Monika and Sauermann, Ulrike and Bredl, Simon and Deml, Ludwig and Ignatius, Ralf and Norley, Steve and Racz, Paul and Tenner-Racz, Klara and Steinman, Ralph M. and Wagner, Ralf and Ueberla, Klaus (2006) Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. VIROLOGY, 351 (1). pp. 133-144. ISSN 0042-6822,
Full text not available from this repository. (Request a copy)Abstract
Vaccination with exogenous antigens such as recombinant viral proteins, immunodeficiency virus-derived whole inactivated virus particles, or virus-like particles (VLP) has generally failed to provide sufficient protection in animal models for AIDS. Pseudotyping VLPs with the vesicular stomatitis virus G protein (VSV-G), which is known to mediate entry into dendritic cells, might allow more efficient stimulation of immune responses. Therefore, we pseudotyped noninfectious immunodeficiency virus-like particles with VSV-G and carried out a preliminary screen of their immunogenicity and vaccination efficacy. Incorporation of VSV-G into HIV-1 VLPs led to hundred-fold higher antibody titers to HIV-1 Gag and enhancement of T cell responses in mice. Repeated vaccination of rhesus monkeys for 65 weeks with VSV-G pseudotyped simian immunodeficiency virus (SIV)-like particles (VLP[G]) provided initial evidence for efficient suppression of viral load after mucosal challenge with the SIVmac239 virus. Challenge of monkeys after a 28 week vaccination regimen with VLP[G] led to a reduction in peak viremia, but persistent suppression of viral load was not achieved. Due to limitations in the number of animals available for this study, improved efficacy of VSV-G pseudotyped VLPs in nonhuman primates could not be demonstrated. However, mouse experiments revealed that pseudotyping of VLPs with fusion-competent VSV-G clearly improves their immunogenicity. Additional strategies, particularly adjuvants, should be considered to provide greater protection against a challenge with pathogenic immunodeficiency virus. (c) 2006 Elsevier Inc. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CYTOTOXIC T-CELLS; RHESUS MACAQUES; SINGLE-CYCLE; NEUTRALIZING ANTIBODIES; ENVELOPE GLYCOPROTEINS; MUCOSAL CHALLENGE; IMMUNE-RESPONSES; GENE-TRANSFER; INFECTION; VACCINE; SIV; VLP; vaccine; immunization; HIV |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 09 Feb 2021 15:07 |
| Last Modified: | 09 Feb 2021 15:07 |
| URI: | https://pred.uni-regensburg.de/id/eprint/34292 |
Actions (login required)
 |
View Item |
